Multiple myeloma: epidemiology and therapeutic options
1Department of Internal Medicine, Division ofHematology and Oncology, University of California-Davis Cancer Center, Sacramento, USA.
Managed Care (Langhorne, Pa.)
|December 20, 2008
Summary
Multiple myeloma is incurable, but new treatments are improving patient care. Understanding individual differences in disease and treatment response allows for personalized medical approaches.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Multiple myeloma is a complex plasma cell malignancy with significant heterogeneity.
- Despite advances, myeloma remains an incurable hematologic cancer.
- Treatment strategies are evolving due to diverse disease presentations and patient responses.
Purpose of the Study:
- To review the current landscape of multiple myeloma management.
- To highlight the impact of novel therapeutic agents.
- To emphasize the importance of personalized medicine in myeloma care.
Main Methods:
- Literature review of recent clinical trials and therapeutic developments.
- Analysis of factors influencing disease manifestation and treatment efficacy.
- Synthesis of data on patient-specific responses to novel agents.
Main Results:
- Novel treatment agents have markedly improved outcomes for multiple myeloma patients.
- Significant variability exists in how myeloma manifests and how patients respond to therapy.
- Personalized treatment strategies are increasingly crucial for optimizing patient care.
Conclusions:
- While myeloma remains incurable, therapeutic advancements offer improved management options.
- Tailoring treatment based on individual disease characteristics and patient response is essential.
- The future of myeloma care lies in further refining personalized therapeutic approaches.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...